Exploring the Genetic Correlation between Periodontal and Respiratory Diseases

Exploring the Genetic Correlation between Periodontal and Respiratory Diseases

By

Pooja Singh, Umesh Pratap Verma
and Ajay Kumar Verma

Cambridge
Scholars
Publishing

Exploring the Genetic Correlation between Periodontal and Respiratory Diseases

By Pooja Singh, Umesh Pratap Verma and Ajay Kumar Verma

This book first published 2024

Cambridge Scholars Publishing

Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK

British Library Cataloguing in Publication Data
A catalogue record for this book is available from the British Library

ISBN (10): 1-0364-0210-X
ISBN (13): 978-1-0364-0210-5

TABLE OF CONTENTS

PREFACE

In the midst of a groundbreaking discovery on the genetic foundations of disease, the complex connection between respiratory disease and periodontitis has become an intriguing area of study. This book represents the culmination of our collective efforts to unravel the enigmatic connections between these seemingly disparate health conditions, offering a compelling synthesis of current research and insights into the shared genetic mechanisms at play. In the vast realm of medical research, our focus has been on understanding how our genetic makeup influences various diseases.

While this journey presented its challenges, we have strived to present the information in a clear and accessible manner. We recognize that the field of genetics is constantly evolving, and there is always more to learn.

Our aspiration is for this book to shed light on how our genes can impact these diseases. Not only facilitates a deeper understanding of the genetic foundations of periodontitis and respiratory disease but also stimulates further discourse and innovative approaches to personalized care. We invite readers to embark on this journey of exploration, which we trust will serve as a stepping stone for future advancements in the field of genetic research and healthcare practice.

List of Abbreviations

LGI	Low grade inflammation
CVDs	Cardiovascular diseases
CP	Chronic periodontitis
PD	Periodontal disease
LPS	Lipopolysaccharides
CAL	Clinical attachment loss
PAD	Peptidyl arginine deaminase
FICZ	6-Formylindolo[3,2-b]carbazole
CRP	C-reactive protein
NETs	Neutrophil extracellular traps
CKD	Chronic kidney disease
HMT	Histone Methyltransferase
HDAC	Histone Deacetylase
NPY	Neuropeptide Y
TLR	Toll-like receptor
PTGS 2	Prostaglandin-Endoperoxide Synthase 2
CpG	Cytosine-phosphate-Guanine
SAM	S-Adenosyl Methionine
HDACi	Histone Deacetylase Inhibitor
DNMT	DNA methyltransferase
BET	Bromodomain and Extraterminal Domain

CHAPTER 1

GENETICS: UNDERSTANDING THE FUNDAMENTALS

Introduction

In a primer on genomic medicine, Guttmacher and Collins offered a valuable distinction between genetics and genomics. According to their perspective, genetics focused on the examination of individual genes and their isolated effects. In contrast, genomics expanded the scope to encompass the comprehensive exploration of all the genes within the genome, with a particular emphasis on understanding their collective functions and intricate interactions. This broader perspective provided a deeper understanding of the complex dynamics at play within the genome, paving the way for advancements in genomic medicine and the exploration of holistic approaches to studying genetic information. Guttmacher and Collins defined genetics as the study of single genes and their effects, while genomics encompassed the study of all genes in the genome and their functions and interactions. This definition suggests a quantitative difference between the two fields. Furthermore, in medical and public health applications, there is a qualitative shift from the concept of disease in genetics to the concept of information in genomics. This shift can be viewed as a continuum, ranging from single gene disorders to the analysis of genetic information from multiple loci in somatic cells. (1)

In addition to genomics, various specialized branches of molecular biology have emerged, each with its own distinct focus and applications. These include pharmacogenomics, which investigates the genetic factors influencing an individual's response to drugs (2), nutrigenomics, which explores the interplay between genetics and nutrition to understand how diet affects health (3), metabonomics, which examines the metabolic profile of biological samples for insights into physiological changes (4), transcriptomics,

which analyzes the entire set of RNA molecules in a cell to study gene expression (5), proteomics, which studies the structure, function, and interactions of proteins within a cell or organism (6), toxico-genomics, which explores the effects of toxic substances on gene expression (7), and many others. These specialized branches highlight the diverse applications of molecular biology in uncovering the intricate mechanisms underlying various biological processes.

Pharmacogenomics

Pharmacogenomics is a field dedicated to unraveling the genetic mechanisms underlying variable drug response with the goal of implementing genetic testing to enhance drug efficacy and minimize toxicity. By understanding the genetic basis of individual differences in drug response, this knowledge can be leveraged to broaden the application of existing drugs to new indications and facilitate the development of novel therapeutic interventions. Notably, there are well-established instances where genetically-determined variability in drug response is influenced by common single DNA variants within a population. These variants often exhibit substantial effects and yield clearly distinguishable metabolizer phenotypes, further highlighting the importance of genetic factors in shaping drug response (8).

Pharmacogenomic variability primarily encompasses variations in pharmacodynamic processes. During the 1960s and 1970s, the advancement of robust methodologies for measuring drug concentrations in plasma and various body locations played a crucial role in detecting individuals with unusual pharmacokinetic profiles. These outliers displayed notably high or low plasma drug concentrations, which were associated with varying levels of drug effectiveness or the occurrence of adverse drug reactions (ADRs). Recent investigations have revealed that genetic variations in key genes responsible for drug metabolism and transport are the underlying factors contributing to the diverse responses people have to medications. More contemporary research approaches, such as genome-wide association studies (GWAS), have not only confirmed the importance of these candidate genes but have also unveiled new genomic regions associated with variable drug reactions. Human genetics has emerged as a pivotal contributor to the

development of novel therapies, particularly in the context of rare Mendelian diseases. For example, consider cystic fibrosis, where genetic mutations in the CFTR gene disrupt the normal functioning of the CFTR protein, leading to abnormal ion channel conductance and impaired cell surface trafficking. This understanding of the genetic basis of diseases like cystic fibrosis has opened doors to targeted therapies and precision medicine approaches. In response to this understanding, a drug called ivacaftor, which acts as a conductance defect corrector, has shown promising results in improving the functional status of individuals affected by cystic fibrosis. This highlights how insights gained from human genetics can lead to the development of targeted therapies that address specific molecular defects associated with genetic diseases (10). To provide targeted treatment for patients with cystic fibrosis, specific germ-line variants have been identified and tested in clinical trials or in vitro to assess their response to ivacaftor, leading to its marketing for these specific variants. The primary functional impairment in cystic fibrosis predominantly revolves around the malfunction of channels, preventing them from correctly reaching the cell surface. Consequently, lumacaftor, in combination with ivacaftor, has been developed and made available in the market to address this particular indication. These advancements underscore the progress made in tailoring therapies to target the underlying genetic mechanisms of cystic fibrosis, offering new possibilities for managing the condition more effectively (11). The Ubiquitous Pharmacogenomics research group of the European Union is assessing a preventative strategy in the PREPARE research. This approach involves testing 12 genes to identify genetic factors related to adverse drug reactions (ADRs) associated with 43 target drugs. The study's objectives include lowering the frequency of ADRs and improving patient safety in pharmacotherapy (12).

Nutrigenomics

After the human genome has been sequenced and the emergence of omics-based approaches, the field of "Nutritional Genomics" has gained prominence, replacing the previous term "nutrient-gene interactions" (13). It is well known that different genetic polymorphisms can affect how proteins are built and work. Two main areas make up nutritional genomics:

first, nutrigenomics examines how dietary elements interact with the gene to affect changes in proteins and metabolic metabolism. Secondly, Nutrigenetics focuses on identifying individual responses to dietary components based on genetic differences. This field offers insights into the intricate relationship between nutrition, genetics, and personalized health outcomes. (14).

As environmental elements that interact with genetic material, nutrients are extremely important. It is generally known that dietary components that function as cofactors or substrates in metabolic pathways play important roles in DNA metabolism and repair. The effect of cofactors, micronutrient excesses or deficiencies, or both, on the precision of DNA replication and repair, however, is still comparatively poorly known. Although nutrients might affect the emergence of particular phenotypes, it is crucial to take the individual genotype into account when estimating the response to a given nutrient. The interplay between genotype and nutrient response adds an additional layer of complexity to the understanding of how nutrients shape biological outcomes (16).

There are two different levels at which the genome and nutrition interact. First of all, nutrients have the power to alter gene expression, which in turn alters a person's phenotype. They can affect several biological processes by either inducing or suppressing gene expression. Second, the bioactivity of crucial metabolic pathways and mediators can be impacted by single nucleotide polymorphisms (SNPs) in the genome. These genetic variants can modify how well foods interact with these pathways, affecting the physiological response that results. This bidirectional interaction highlights the dynamic interplay between nutrients and the genome, with implications for individual health and well-being (15).

Nutritional Genomics

The term "nutritional genomics," also known as "nutrigenomics," describes the scientific exploration of the intricate interplay between nutrients and cellular/genetic processes (16). This term encompasses the interdisciplinary field that combines biochemistry, genomics, and human nutrition to study

the molecular-level reactions and interactions occurring within the context of nutrition (17).

The term "nutrigenetics" was first introduced by Dr. R.O. Brennan in 1975 in his book titled "Nutrigenetics" (18). Nutrigenetics is a scientific discipline that centers on the examination of how an individual's genetic makeup affects their unique response to dietary factors (19). The study of gene-nutrient interactions is an evolving field in science. The idea that detrimental interactions between one's diet and their genetic makeup can play a role in the development of diseases is not a recent revelation. In fact, the concept of an unsuitable diet for a particular genotype has the potential to elevate the risk of both monogenic (caused by a single gene) and polygenic (involving multiple genes) disorders. This underscores the importance of considering genetic factors when evaluating the impact of diet on health. This emphasizes the importance of understanding the interplay between genetic factors and dietary choices in the context of disease risk and prevention. (16, 20). Genetic polymorphisms can have a significant impact on an individual's response to environmental factors, including changes in enzymatic activity that affect the levels and efficacy of chemicals and their metabolites (21). Furthermore, genetic variations are significant contributors to metabolic disorders, encompassing conditions like phenylketonuria (PKU), deficiencies in long-chain fatty acid oxidation, and compromised iron absorption, as observed in hemochromatosis. These conditions can often be effectively managed through dietary restrictions tailored to the individual's genetic profile. The influence of genetic variations on response to environmental elements highlights the importance of personalized approaches to diet and lifestyle modifications for managing and mitigating the effects of certain metabolic disorders (22).

Nutrigenomics is a field of study with the primary objective of examining the impacts of diverse nutrients, encompassing both macronutrients and micronutrients, on the genome (19). It delves into the complex interplay between genes, nutrients, bioactive compounds found in foods, and how all of these factors collectively influence human health (23). Nutrigenomics encompasses the study of how nutrients can influence transcriptional activity, gene expression, and the various responses associated with genetic variants. This field explores the intricate connections between dietary

components and the functioning of genes, shedding light on how nutrition can impact our genetic makeup and subsequent biological responses. Many nutrition-related disorders, such as metabolic syndromes, obesity, type 2 diabetes, cardiovascular diseases, and certain types of cancers, are complex conditions influenced by multiple genes, their variants, and various environmental factors, particularly diet (24). The study of Nutrigenomics provides insights into the polygenic and multifactorial nature of these pathologies and their relationships with genetic and dietary factors. The discipline known as "nutritional epigenetics" is primarily concerned with investigating gene expression changes that occur without any modifications to the underlying DNA sequence. Epigenetic regulation, a key process in development, plays a pivotal role in establishing and maintaining stable gene expression patterns or repression within specific cell types and during various developmental stages (25). Epigenetic changes possess the capacity to impact crucial cellular mechanisms, encompassing cell cycle regulation, DNA damage response, programmed cell death (apoptosis), cellular invasion, genomic imprinting, and the aging process. These epigenetic modifications can have far-reaching effects on various aspects of cell biology and overall health. Understanding the interplay between nutrition and epigenetic modifications can provide insights into how dietary factors can influence gene expression patterns and cellular functions, contributing to health and disease outcomes (26).

It is evident that even minor damages to the genome can have significant impacts on overall human health. The DNA metabolism and repair processes depend on a variety of dietary factors that serve as either cofactors or substrates. These dietary components play essential roles in supporting and facilitating the proper functioning of processes involved in DNA maintenance and repair. Adequate nutritional requirements play a vital role in preventing DNA oxidation (such as through the intake of antioxidants like carotenoids, vitamin E, and vitamin C), minimizing uracil incorporation into DNA (via folate), ensuring proper methylation of CpG sites in DNA (involving methionine, choline, folate, and vitamin B12), serving as cofactors or constituents of DNA repair enzymes (including zinc and magnesium), and maintaining optimal telomere length (with contributions from niacin and folate) (27-29). While diet and nutrition are commonly

recognized as potential risk factors in cancer development, they also hold promise in preventing and even treating cancer (30,31). Understanding the precise role of diet in these processes is a significant objective in the field of nutrigenetics/nutrigenomics. Emerging studies in nutrigenomics indicate that micronutrients, including certain vitamins and trace minerals, as well as macronutrients such as dietary fiber, can be effective in both cancer prevention and treatment. Specifically, they target key characteristics of tumor cells, such as their unlimited replicative potential and ability to metastasize (32). An illustrative example is the use of flaxseeds in the treatment of breast cancer, where a lignan present in flaxseeds is converted into a substance that binds to estrogen receptors, ultimately reducing cell growth. These findings highlight the potential of dietary interventions and the underlying molecular mechanisms in combating cancer, emphasizing the importance of nutrigenomic research in this field. (33, 34).

Metabonomics

The concept of the "metabolome," which encompasses the entire set of small molecules present in a biological system or fluid, was first introduced by Oliver and colleagues in 1998 as part of their groundbreaking research on yeast metabolism. Building upon this concept, the field of metabolomics emerged as the study of the metabolome, encompassing the analysis of small molecules in biological samples. While some groups may use alternative terms such as metabonomics or metabolic profiling, metabolomics is the most widely used and accepted term in the field (35).

The early use of gas chromatography-mass spectrometry to analyze and profile metabolites in clinical urine samples can be regarded as one of the pioneering instances of metabolomics, with its origins dating back to the 1970s (36-38). Additionally, the utilization of nuclear magnetic resonance spectroscopy for profiling clinical samples was pioneered by Nicholson and others in the 1980s (39-41). Subsequently, the incorporation of mass spectrometry with liquid chromatography (42) and capillary electrophoresis (43) expanded the analytical techniques available for metabolomics research. These advancements in analytical methodologies have paved the way for comprehensive investigations into the small molecule composition of biological systems, enabling researchers to unravel the intricate

metabolic pathways and gain insights into the functional aspects of various organisms.

Biochemistry of the Metabolome

In contrast to the relatively limited set of building blocks found in the genome and proteome, the realm of metabolites encompasses an extensive array of organic structures and functional groups, granting them the ability to carry out diverse biochemical functions. Metabolites encompass a wide range of molecules, including amino acids, phosphosugars, nucleotides, as well as their precursors and degradation products. These molecules serve as the fundamental building blocks for the intricate biochemical processes within living organisms. While metabolites possess intrinsic functional properties based on their structures, they do not exist in isolation within biological systems. Instead, they interact with enzymes and undergo chemical modifications as part of anabolic (biosynthetic) and catabolic (degradative) pathways. These enzymatic reactions and transformations contribute to the dynamic nature of metabolism, allowing organisms to synthesize essential molecules, generate energy, and eliminate waste products (44).

Metabolomics employs a range of competing platforms for analysis. The primary techniques employed in metabolomics encompass liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR). These methods are integral for profiling and analyzing metabolites in biological samples. Capillary electrophoresis, introduced by Soga (43), is increasingly popular for separating charged metabolites prior to mass spectral analysis. Additionally, high-throughput spectroscopic profiling techniques, such as FT-IR (45,46) and Raman spectroscopy (47,48) have gained prominence.

Transcriptomics

Transcriptomics is the field of study dedicated to investigating the transcriptome. The term "transcriptome" was introduced by Charles Auffray (49) and refers to the entirety of RNA molecules expressed in a particular entity, such as a cell, tissue, or organism. This area of research focuses on

understanding and analyzing the patterns of gene expression at the RNA level within biological systems (50,51). Transcriptomics is a comprehensive field that covers multiple facets of RNA, including transcription processes, expression levels, functions, cellular localization, transport mechanisms, and degradation pathways. Additionally, it explores the structural characteristics of transcripts and their associated genes, including transcription start sites, 5' and 3' end sequences, splicing patterns, and posttranscriptional modifications (52). Transcriptomics encompasses the study of all types of transcripts, such as messenger RNAs (mRNAs), microRNAs (miRNAs), and various long noncoding RNAs (lncRNAs). Initially, our understanding of the transcriptome was built upon gene predictions and traditional methods that involved the creation of complementary DNA (cDNA) clones to generate expressed sequence tags (ESTs). These ESTs were then sequenced using automated Sanger sequencing technology. This approach, which was prominently employed in projects like the Human Genome Project, played a pivotal role in providing valuable insights into the composition and dynamics of the transcriptome (53).

Competing endogenous ribonucleic acid (ceRNA) ceRNA refers to RNA molecules that compete for microRNAs, regulating the expression of other RNA transcripts.

Complementary deoxyribonucleic acid (cDNA) is a type of DNA molecule that is synthesized from an mRNA (messenger RNA) template. This synthesis process is typically accomplished using an enzyme called reverse transcriptase.

Expressed sequence tags (ESTs) are short sequences derived from complementary DNA (cDNA). They are typically small fragments of cDNA sequences that represent portions of expressed genes.

Fluorescent in situ RNA sequencing (FISSEQ): A sequencing method using fluorescent dNTP incorporation and polonies.

Long noncoding RNAs (lncRNAs) are a class of RNA molecules that are characterized by their length, typically exceeding 200 nucleotides, and their lack of protein-coding potential.

Messenger RNA (mRNA) is a type of RNA molecule that serves as a template for protein synthesis within cells. It carries genetic information from the DNA in the cell's nucleus to the ribosomes, which are the cellular structures responsible for protein synthesis.

MicroRNA (miRNA): Small noncoding RNA molecules involved in gene regulation.

Noncoding RNA (ncRNA): RNA molecules that do not code for proteins.

Piwi-interacting RNAs (piRNAs) are a class of small noncoding RNA molecules that play a crucial role in protecting the genome by suppressing the activity of transposable elements, which are sequences that can move within the genome and potentially disrupt gene function.

RNA sequencing (RNA-seq) is a powerful molecular biology technique used for mapping and quantifying the RNA molecules transcribed from the genome of an organism.

Sequencing by Oligonucleotide Ligation and Detection (SOLiD) is a next-generation sequencing (NGS). SOLiD technology was designed to efficiently and accurately sequence DNA and RNA molecules for a variety of applications, including whole-genome sequencing, transcriptomics, and epigenetics research.

Serial analysis of gene expression (SAGE): Technique for generating small tags corresponding to mRNA fragments.

Single-Molecule Real-Time sequencing (SMRT sequencing) is a next-generation sequencing technology that enables the real-time observation of the DNA synthesis process at the level of individual DNA molecules. It is a single-molecule sequencing approach that offers several advantages, including longer read lengths and the ability to detect base modifications, making it valuable for various genomics applications.

Small nuclear RNAs (snRNAs) are a class of small RNA molecules that are primarily located in the nucleus of eukaryotic cells. These molecules play essential roles in various nuclear processes, particularly in the splicing

of pre-messenger RNA (pre-mRNA) molecules during the process of mRNA maturation.

Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that are primarily found in the nucleolus of eukaryotic cells. They play crucial roles in the modification and processing of ribosomal RNA (rRNA) and other non-coding RNAs. SnoRNAs are often associated with small nucleolar ribonucleoprotein particles (snoRNPs) in the nucleus.

snoRNA-derived RNA (sdRNA): Small noncoding RNA with distinct sequences detected across eukaryotes.

In a groundbreaking study, serial analysis of gene expression (SAGE) was used to characterize gene expression patterns in the human pancreas by analyzing 1000 tags (54). The development of RNA-seq has revolutionized transcriptomics by enabling the sequencing of the entire transcriptome (55,56). Traditional sequencing approaches, such as EST (Expressed Sequence Tag) sequencing, primarily detect highly abundant transcripts within a sample. In contrast, RNA sequencing (RNA-seq), when performed with sufficient sequencing depth, has the capacity to comprehensively capture nearly the entire transcriptome (57). RNA-seq offers the advantage of conducting genome-wide assessments of transcripts across a broad spectrum of expression levels (58). Unlike array-based technologies, which are limited to the detection of known transcripts, RNA-seq serves as a powerful discovery tool. It can identify previously unknown or novel transcripts, including long noncoding RNAs (lncRNAs), and is also widely employed for tasks such as analyzing differential gene expression and characterizing alternative splicing events (59). Most RNA-seq approaches involve converting extracted mRNAs or total RNAs into cDNA libraries containing sequencing adapters. Traditionally, next-generation sequencing (NGS) platforms have produced short sequence reads, typically spanning a range of 35 to 500 base pairs (bp) in length. These short reads were common in early NGS technologies and were suitable for many genomic applications, including genome assembly, variant calling, and transcript quantification (59,60). This poses computational challenges as reconstructing full-length transcripts requires high-powered computing systems with substantial memory and multiple cores. Additionally, these platforms are associated

with relatively high error rates and potential biases in coverage, presenting informatics obstacles (61,62). Advancements in assembly algorithms and data quality have facilitated the development of newer RNA sequencing technologies, such as single-molecule, real-time sequencing technology (SMRT) and nanopore sequencers (63,64). Recent advancements in sequencing technologies have introduced longer read lengths, with some platforms capable of spanning several kilobases (thousands of base pairs) in a single sequencing run. These extended read lengths have made it possible to sequence entire RNA transcripts without the need for assembly. For example, the Single-Molecule Real-Time (SMRT) sequencing platform, developed by Pacific Biosciences, offers an average read length of approximately 3,000 base pairs, with the potential to exceed 20,000 base pairs in some cases. This substantial read length allows for the sequencing of most RNA transcripts in a single read, although additional reads may be employed to enhance coverage and throughput as needed (57).

A recent advancement in transcriptomics is the fusion of RNA-seq and fluorescent in situ hybridization (FISH), resulting in a technique termed fluorescent in situ RNA-seq (FISSEQ). FISSEQ involves in situ reverse transcription of RNA, followed by rolling-circle amplification to create DNA "nanoballs." These nanoballs are then sequenced within cells using SOLiD (sequencing by oligonucleotide ligation and detection) technology. This integrated approach allows researchers to study gene expression with spatial precision, providing insights into the distribution of RNA transcripts within native cellular environments. SOLiD sequencing employs a unique approach using fluorescently labeled two-base probes, which hybridize sequentially. This sequential hybridization enables imaging and the precise determination of the transcript sequence within each DNA nanoball. In the initial publication introducing FISSEQ, the researchers successfully sequenced more than 500 nanoballs in primary human fibroblasts, achieving a remarkable median base error rate of just 0.64%. Although further refinements are required, the capability to simultaneously acquire both sequence data and positional information marks a notable advancement in the field of transcriptomics research (65). Traditional high-throughput technologies in transcriptomics involve converting RNA into cDNA. However, novel approaches like nanopore sequencing now enable direct

sequencing of RNA molecules, eliminating the need for reverse transcription and sequence assembly, which can introduce errors (66). In direct sequencing technologies, RNA is passed through a solid state nanopore or a molecular nanopore in the presence of an electrical field. Each RNA base (rA, rC, rG, or rU) passing through the pore causes a distinct change in the current flow. To detect these changes, the RNA is temporarily immobilized by binding to a capture molecule, slowing down the passage of bases through the pore. Molecular nanopores, such as α-hemolysin, originally used for direct DNA sequencing, can be modified for RNA-seq by targeted mutation and combined with capture strategies like biotin-streptavidin binding. Since the 1950s, it has been known that ribosomal RNA (rRNA) and transfer RNA (tRNA) have biological functions beyond protein-coding. Recent advancements in RNA technologies have revealed the existence of various classes of noncoding RNAs (ncRNAs). These ncRNAs are now recognized to play crucial roles in regulating other RNA molecules and modulating the transcriptome. A well-studied example is microRNAs (miRNAs), which are known to bind to target mRNA transcripts and induce their degradation (67). Small nuclear RNAs (snRNAs) play critical roles, potentially even catalytic roles, in the splicing process of mRNA transcripts. These snRNAs are involved in the formation of spliceosomes, which are complex molecular machines responsible for accurately removing introns and joining exons together during mRNA maturation. Their presence and activity are essential for ensuring the proper splicing of pre-mRNA molecules into functional mRNA molecules (68,69).

Small nucleolar RNAs (snoRNAs) are primarily involved in modifying other RNA species, such as rRNA and snRNA. They play a crucial role in guiding chemical modifications, such as methylation and pseudouridylation, of specific nucleotides within these target RNAs. snoRNAs are often derived from spliced introns of transcripts and can escape degradation by forming protein complexes. In some cases, snoRNAs may undergo additional processing to generate snoRNA-derived RNAs (sdRNAs), which are noncoding RNAs similar to miRNAs. sdRNAs may have regulatory functions in gene expression, contributing to the intricate network of RNA-mediated regulation in cells (70,71).

Recent studies have highlighted the multifaceted roles of long noncoding RNAs (lncRNAs) in transcriptional regulation. They can directly interact with the transcription machinery and specific transcription factors to influence gene expression. At the posttranscriptional level, lncRNAs can impact mRNA processing, including through their function as natural antisense transcripts (72,73). They also play roles in translation control and mRNA stability. The complexity of transcriptomic interactions is vast, as evidenced by the abundance of different RNA classes. For instance, the human miRNA class alone comprises over 2500 distinct members, while the number of lncRNAs exceeds 10,000. The Piwi-interacting RNA (piRNA) class, which participates in epigenetic gene regulation, is even larger, potentially consisting of hundreds of thousands or even millions of distinct piRNAs (74-76).

The complexity of the transcriptome is further emphasized by the tissue- and time-specific expression patterns observed in many noncoding RNAs (ncRNAs). These ncRNAs exhibit dynamic regulation, adding an additional layer of intricacy to their functional roles (77). Another intriguing class of RNA molecules that has gained attention through deep sequencing techniques is circular RNA. Circular RNAs can be derived solely from exons, solely from introns, or a combination of both. Through alternative circularization and splicing, individual human genes have the potential to generate multiple circular RNAs at thousands of genomic loci. This suggests that the class of circular RNA encompasses a large number of members, contributing yet another dimension to the transcriptome and its regulatory mechanisms (78).

Furthermore, the discovery of over one hundred RNA modifications, such as methylation, uridylation, and various tailing motifs, adds another layer of complexity to the transcriptome. These modifications provide additional regulatory mechanisms that can influence the function and stability of RNA molecules. Additionally, it has been recognized that different RNA species can engage in cross-talk and regulatory interactions. This has given rise to the concept of competing endogenous RNA (ceRNA), wherein a network of RNA molecules regulates each other's expression by competing for binding to shared microRNAs (miRNAs). This ceRNA network represents a sophisticated regulatory mechanism within the transcriptome (79).

Proteomics

The advent of mRNA arrays has facilitated the analysis of thousands of gene transcripts by allowing the synthesis of mRNA probes that can be coupled to solid surfaces. This technology has enabled researchers to study the expression levels of genes on a large scale. Following these advancements in genome and transcriptome analysis, there was a shift in focus towards studying proteins, leading to the development of proteomics. Proteomics involves analyzing the entire set of proteins present in a cell, tissue, or organism under specific conditions. The field of proteomics has greatly benefited from technological and instrumental advancements, including improvements in mass spectrometry (MS) technology, protein fractionation techniques, and bioinformatics tools. However, one of the challenges in proteomics is the inherent complexity of the proteome, which adds to the intricacy of analyzing and understanding protein function and interactions (80). Proteomics relies on fractionating complex protein mixtures, using techniques such as two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) or liquid chromatography (LC). Mass spectrometry (MS) is then used to identify individual proteins, and bioinformatics is employed for data analysis. 2D-PAGE, developed over 30 years ago, remains a commonly used method in proteomics, while LC-based methods offer high-resolution separation. The choice of technique depends on the research goals and sample characteristics (81).

Advances in 2D-PAGE technology now enable the resolution of thousands of proteins in a single gel. Besides separating protein mixtures, 2D-PAGE allows for the comparison of protein abundances between different proteomes. In a typical study, proteomes from two cell populations are extracted and fractionated on separate gels. In proteomics, a widely used technique called two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) allows for the separation of complex protein mixtures and comparison of protein abundances. Recent advancements have enabled the resolution of thousands of proteins in a single gel, enhancing its capabilities. During a typical 2D-PAGE experiment, proteins from different cell populations are fractionated on separate gels, and the more intensely stained protein spots on one gel are carefully excised. Enzymatic digestion with trypsin is then performed on the excised proteins, producing tryptic

peptides. These peptides are extracted from the gel and subjected to mass spectrometry (MS) or tandem MS (MS/MS) analysis, generating raw data for protein identification. Dedicated software is employed to match this data against extensive genomic or protein sequence databases. Despite some criticisms, 2D-PAGE remains a fundamental and widely utilized technology in the field of proteomics. To visualize the proteins, which are mostly colorless, appropriate visualization methods are employed (82-83).

Conclusion

In conclusion, the field of genomics has undergone a remarkable transformation, significantly expanding our comprehension of genetics. This evolution entails a shift from the conventional focus on individual genes and their discrete effects, as encapsulated in the realm of genetics, to the far-reaching exploration of the entire genome, which characterizes the domain of genomics. This paradigm shift has not only empowered researchers to scrutinize the functions of individual genes but has also facilitated the revelation of the intricate interactions and the collective functions of the entire complement of genes within an organism's genetic repertoire. These developments in genomics have ushered in a new era of scientific exploration and medical practice. With the advent of genomic medicine, and the emergence of specialized branches such as pharmacogenomics, nutrigenomics, and transcriptomics, we are now equipped with the tools to delve even deeper into the profound influence of genetic information on health and disease. By deciphering the intricate network of noncoding RNAs and grappling with the multifaceted nature of the proteome, we gain additional layers of insight into the molecular complexities that underpin life's fundamental processes.

It is noteworthy that the integration of these various "omics" approaches is poised to play an increasingly pivotal role in the future of personalized medicine. This integration not only enhances our understanding of the molecular underpinnings of biological phenomena but also holds immense promise in tailoring medical interventions to individual genetic profiles, thus paving the way for more precise and effective healthcare strategies. As we continue to harness the power of genomics and its allied disciplines, we

are on the cusp of transformative breakthroughs that promise to shape the future of both medical science and clinical practice.

References

1. Guttmacher, AE, and FS Collins. "Genomic Medicine: A Primer." *New England Journal of Medicine* 347 (2002): 1512–1520.
2. Amin, AR. "Pharmacogenomics: Hype, Hope, or Metamorphosis of Molecular Medicine and Pharmaceuticals." *Trends in Pharmacological Sciences* 23 (2002): 583.
3. van Ommen, B, and R Stierum. "Nutrigenomics: Exploiting Systems Biology in the Nutrition and Health Arena." *Current Opinion in Biotechnology* 13 (2002): 517–521.
4. Robosky, LC, DG Robertson, JD Baker, S Rane, and MD Reily. "In Vivo Toxicity Screening Programs Using Metabonomics." *Combinatorial Chemistry & High Throughput Screening* 5 (2002): 651–662.
5. Garlow, SJ. "And Now, Transcriptomics." *Neuron* 34 (2002): 327–328.
6. Stanley, MW. "Proteomics." *American Journal of Clinical Pathology* 118 (2002): 825–826.
7. Schmidt, CW. "Toxicogenomics: An Emerging Discipline." *Environmental Health Perspectives* 110 (2002): A750–A755.
8. Roden, DM, HL McLeod, MV Relling, MS Williams, GA Mensah, and JF Peterson, et al. "Pharmacogenomics." *Lancet* 394, no. 10197 (2019): 521–532.
9. Motsinger-Reif, AA, E Jorgenson, MV Relling, et al. "Genome-wide Association Studies in Pharmacogenomics: Successes and Lessons." *Pharmacogenetics and Genomics* 23 (2013): 383–394.
10. Whiting, P, M Al, L Burgers, et al. "Ivacaftor for the Treatment of Patients with Cystic Fibrosis and the G551D Mutation: A Systematic Review and Cost-Effectiveness Analysis." *Health Technology Assessment* 18 (2014): 1–106.
11. Wainwright, CE, JS Elborn, BW Ramsey, et al. "Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR." *New England Journal of Medicine* 373 (2015): 220–231.
12. van der Wouden, CH, A Cambon-Thomsen, E Cecchin, et al. "Implementing Pharmacogenomics in Europe: Design and Implementation

Strategy of the Ubiquitous Pharmacogenomics Consortium." *Clinical Pharmacology & Therapeutics* 101 (2017): 341–358.

13. Shils, ME, M Shike, AC Ross, B Caballero, and R J-Cousins. *Modern Nutrition in Health and Disease.* (2006): 10:39.
14. Subbiah, MT. "Nutrigenetics and Nutraceuticals: The Next Wave Riding on Personalized Medicine." *Translational Research* 149, no. 2 (2007): 55–61.
15. Farhud, D, M Zarif Yeganeh, and M Zarif Yeganeh. "Nutrigenomics and Nutrigenetics." *Iranian Journal of Public Health* 39, no. 4 (2010): 1-14.
16. Kaptur, J, and LR Raymond. "Nutritional Genomics: The Next Frontier in the Post-Genomic Era." *Physiological Genomics* 16 (2004): 167-77.
17. Milner, JA. "Molecular Targets for Bioactive Food Components." *Journal of Nutrition* 134, no. 9 (2004): 2492S-2498S.
18. Simopoulos, AP. "Genetic Variants in the Metabolism of Omega-6 and Omega-3 Fatty Acids: Their Role in the Determination of Nutritional Requirements and Chronic Disease Risk." *Experimental Biology and Medicine* 235 (2010): 785-95.
19. Mutch, DM David, Wahli Walter, and Williamson Gary. "Nutrigenomics and Nutrigenetics: The Emerging Faces of Nutrition." *FASEB Journal* 19, no. 12 (2005): 1602-16.
20. Ames, BN, I Elson-Schwab, and EA Silver. "High-Dose Vitamin Therapy Stimulates Variant Enzymes with Decreased Coenzyme Binding Affinity (Increased Km): Relevance to Genetic Disease and Polymorphisms." *American Journal of Clinical Nutrition* 75, no. 4 (2002): 616-58.
21. El-Sohemy, A. "Nutrigenetics." *Forum of Nutrition* 60 (2007): 25-30.
22. Palou, A. "From Nutrigenomics to Personalized Nutrition." *Genes & Nutrition* 2, no. 1 (2007): 5–7.
23. El-Sohemy, A. "The Science of Nutrigenomics." *Health Law Review* 16, no. 3 (2008): 5-8.
24. Iacoviello, L, I Santimone, MC Latella, G de Gaetano, and MB Donati. "Nutrigenomics: A Case for the Common Soil between Cardiovascular Disease and Cancer." *Genes & Nutrition* 3, no. 1 (2008): 19-24.

25. Stover, PJ, and MA Caudill. "Genetic and Epigenetic Contributions to Human Nutrition and Health: Managing Genome-Diet Interactions." (2008).
26. Trujillo, E, C Davis, and J Milner. "Nutrigenomics, Proteomics, Metabolomics, and the Practice of Dietetics." *Journal of the American Dietetic Association* 106, no. 3 (2006): 403-13.
27. Fenech, M. "Nutrition and Genome Health." *Forum of Nutrition* 60 (2007): 49-65.
28. Fenech, M. "The Genome Health Clinic and Genome Health Nutrigenomics Concepts: Diagnosis and Nutritional Treatment of Genome and Epigenome Damage on an Individual Basis." *Mutagenesis* 20, no. 4 (2005): 255-69.
29. Fairfield, KM, and RH Fletcher. "Vitamins for Chronic Disease Prevention in Adults: Scientific Review." *Journal of the American Medical Association* 287, no. 23 (2002): 3116-26.
30. Ardekani, AM, and S Jabbari. "Nutrigenomics and Cancer." *Avicenna Journal of Medical Biotechnology* 1 (2009): 9–17.
31. Nicastro, HL, EB Trujillo, and JA Milner. "Nutrigenomics Cancer Prevention." *Current Nutrition Reports* 1 (2012): 37–43.
32. Irimie, AI, C Braicu, S Pasca, et al. "Role of Key Micronutrients from Nutrigenetic and Nutrigenomic Perspectives in Cancer Prevention." *Medicina* 55 (2019).
33. Calado, A, PM Neves, T Santos, et al. "The Effect of Flaxseed in Breast Cancer: A Literature Review." *Frontiers in Nutrition* 5 (2018).
34. De Silva SF, Alcorn J. "Flaxseed lignans as important dietary polyphenols for cancer prevention and treatment: chemistry, pharmacokinetics, and molecular targets." Pharmaceuticals 12 (2019).
35. Oliver SG et al. "Systematic functional analysis of the yeast genome." Trends Biotechnol 16, no. 9 (1998): 373–378.
36. Gates SC, Sweeley CC. "Quantitative metabolic profiling based on gas chromatography." Clin Chem 24, no. 10 (1978): 1663–1673.
37. Jellum E. "Profiling of human body fluids in healthy and diseased states using gas chromatography and mass spectrometry, with special reference to organic acids." J Chromatogr B Biomed Sci Appl 143, no. 5 (1977): 427–462.

38. Politzer I, Dowty B, Laseter J. "Use of gas chromatography and mass spectrometry to analyze underivatized volatile human or animal constituents of clinical interest." Clin Chem 22, no. 11 (1976): 1775–1788.
39. Bales J et al. "Metabolic profiling of body fluids by proton NMR: Self-poisoning episodes with paracetamol (acetaminophen)." Magn Reson Med 6, no. 3 (1988): 300–306.
40. Gartland K et al. "Pattern recognition analysis of high resolution 1H NMR spectra of urine. A nonlinear mapping approach to the classification of toxicological data." NMR Biomed 3, no. 4 (1990): 166–172.
41. Resnick L, Nicholson J, Laragh J. "Calcium metabolism in essential hypertension: relationship to altered renin system activity." In: Fed Proc (1986).
42. Dunn WB, Bailey NJ, Johnson HE. "Measuring the metabolome: current analytical technologies." Analyst 130, no. 5 (2005): 606–625.
43. Soga T et al. "Quantitative metabolome analysis using capillary electrophoresis mass spectrometry." J Proteome Res 2, no. 5 (2003): 488–494.
44. Burgess K, Rankin N. "Metabolomics for the diagnosis of influenza." EBioMedicine (2021): 72:103599.
45. Kaderbhai NN et al. "Functional genomics via metabolic footprinting: monitoring metabolite secretion by Escherichia coli tryptophan metabolism mutants using FT–IR and direct injection electrospray mass spectrometry." *Comp Funct Genomics* 4, no. 4 (2003): 376–391.
46. Keymanesh K, Darvishi MH, Sardari S. "Metabolome comparison of transgenic and non-transgenic rice by statistical analysis of FTIR and NMR spectra." *Rice Sci* 16, no. 2 (2009): 119–123.
47. Ellis DI, Goodacre R. "Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy." *Analyst* 131, no. 8 (2006): 875–885.
48. Harrigan GG, Goodacre R. "Metabolic profiling: its role in biomarker discovery and gene function analysis." Springer, 2003.
49. Pietu G, Mariage-Samson R, Fayein N A et al. "The genexpress IMAGE knowledge base of the human brain transcriptome: A

prototype integrated resource for functional and computational genomics." *Genome Research* (1999): 195–209.
50. Morozova O, Hirst M, Marra M A. "Applications of new sequencing technologies for transcriptome analysis." *Annual Review of Genomics & Human Genetics* 10 (2009): 135–151.
51. Wolf J B. "Principles of transcriptome analysis and gene expression quantification: An RNA-seq tutorial." *Molecular Ecology Resources* 13 (2013): 559–572.
52. Wang Z, Gerstein M, Snyder M. "RNA-Seq: A revolutionary tool for transcriptomics." *Nature Reviews Genetics* 10 (2009): 57–63.
53. Adama M D, Kelley J M, Gocayne J D et al. "Complementary DNA sequencing: Expressed sequence tags and human genome project." *Science* 252 (1991): 1651–1656.
54. Velculescu V E, Zhang L, Vogelstein B, Kinzler K W. "Serial analysis of gene expression." *Science* (1995); 270:484–487.
55. Ozsolak F, Milos P M. "RNA sequencing: Advances, challenges and opportunities." *Nature Reviews Genetics* 12 (2010): 87–98.
56. Marguerat S, Bahler J. "RNA-seq: From technology to biology." *Cellular & Molecular Life Sciences* 67 (2010): 569–579.
57. Martin J A, Wang Z. "Next-generation transcriptome assembly." *Nature Reviews Genetics* 12 (2011): 671–682.
58. Nookaew I, Papini M, Pornputtpong N et al. "A comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to differential gene expression and cross-comparison with microarrays: A case study in Saccharomyces cerevisiae." *Nucleic Acids Research* 40 (2012): 10084–10097.
59. Metzker M L. "Sequencing technologies − the next generation." *Nature Reviews Genetics* 11 (2009): 31–46.
60. Shendure J, Ji H. "Next-generation DNA sequencing." *Nature Biotechnology* 26 (2008): 1135–1145.
61. Guo Y, Li J, Li C I et al. "The effect of strand bias in Illumina short-read sequencing data." *BMC Genomics* 13 (2012): 666.
62. Bahassi E M, Stambrook P J. "Next-generation sequencing technologies: Breaking the sound barrier of human genetics." *Mutagenesis* 29 (2014): 303–310.

63. Mikheyev A S, Tin M M. "A first look at the Oxford nanopore MinION sequencer." *Molecular Ecology Resources* 14 (6) (2014): 1097–1102.
64. Maitra R D, Kim J, Dunbar W B. "Recent advances in nanopore sequencing." *Electrophoresis* 33 (2012): 3418–3428.
65. Lee J H, Daugharthy E R, Scheiman J et al. "Highly multiplexed subcellular RNA sequencing in situ." *Science* 343 (2014): 1360–1363.
66. Ayub M, Bayley H. "Individual RNA base recognition in immobilized oligonucleotides using a protein nanopore." *Nano Letters* 12 (2012): 5637–5643.
67. Lee R C, Feinbaum R L, Ambros V. "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14." *Cell* (1993); 75:843–854.
68. Matera A G, Wang Z. "A day in the life of the spliceosome." *Nature Reviews. Molecular Cell Biology* (2014); 15:108–121.
69. Valadkhan S, Mohammadi A, Jaladat Y, Geisler S. "Protein-free small nuclear RNAs catalyze a two-step splicing reaction." *Proceedings of the National Academy of Sciences* (2009); 106:11901–11906.
70. Bratkovic T, Rogelij B. "The many faces of small nucleolar RNAs." *Biochimica et Biophysica Acta* (2014); 1839:438–443.
71. Falaleeva M, Stamm S. "Processing of snoRNAs as a new source of regulatory non-coding RNAs: snoRNA fragments form a new class of functional RNAs." *BioEssays: News & Reviews in Molecular, Cellular & Developmental Biology* (2008);35:46–54.
72. Beltran M, Puig I, Pena C et al. "A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition." *Genes & Development* (2008);22: 756–769.
73. Faghighi M A, Wahlested C. "Regulatory roles of natural antisense transcripts." *Nature Reviews Molecular Cell Biology* 10 (2009): 637–643.
74. Brennecke J, Aravin AA, Stark A et al. "Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila." *Cell* 128 (2007): 1089–1103.
75. Siomi M C, Sato K, Pezic D, Aravin A A. "PIWI-interacting small RNAs: The vanguard of genome defence." *Nature Reviews Molecular Cell Biology* 12 (2011): 246–258.